Abstract. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. They have gain-of-function mutations of the c-kit receptor tyrosine kinase gene and have been suggested to originate from the interstitial cells of Cajal. A small percentage of GISTs form extragastrointestinal masses. We report a rare case of a GIST originating from the vulva. A 55-year-old woman presented with a vulvar tumor. The tumor was initially diagnosed as a leiomyosarcoma following the first resection. Following a second recurrence the patient was administered chemotherapy. A third recurrence occurred and the patient underwent a third resection. Histology revealed that a bundle of fibrous tumor cells had invaded the connected tissue and muscular coat, and some spindle-shaped and blunt-ended nuclei were detected. Furthermore, immunohistochemical evaluation revealed that the tumor cells exhibited strong and diffuse staining for c-kit and CD34. The recurrent tumor was diagnosed as a GIST and a reevaluation of the original specimens also revealed a GIST. The patient was treated with imatinib, and is currently healthy with no evidence of recurrence at 20 months after the last surgery.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with approximately 70% of the tumors occurring in the stomach, 20-30% in the small intestine and less than 10% in the esophagus, colon and rectum (1) . The most practical and specific diagnostic criterion for GIST is immunohistochemically determined c-kit (CD117) expression (2) . A GIST is considered to be a particular type of tumor that originates from an interstitial cell of Cajal (ICC) or its precursor (2, 3) . ICCs are the pacemakers of the peristaltic movement of the gastrointestinal tract (4) . A small percentage of GISTs form extragastrointestinal masses in the omentum, mesenteries, retroperitoneum, rectovaginal septum and undefined abdominal sites. These tumors are occasionally designated as extragastrointestinal stromal tumors (5) .
We report a rare case of a GIST originating from the vulva, which was initially diagnosed as a leiomyosarcoma and correctly diagnosed following a second recurrence.
Case report
A 55-year-old woman presented with vulvar swelling and pain. She was found to have a tumor that was larger than a hen's egg with a multilobular surface in the left vulva. She underwent resection of the tumor and the tumor was pathologically diagnosed as a leiomyosarcoma. The patient was then referred to our hospital for further examination and treatment for leiomyosarcoma. Pelvic examination revealed no residual tumor in the vulva, and results of a biopsy also indicated no tumor. The specimen from the former hospital was reexamined and confirmed to be a leiomyosarcoma. The patient underwent a simple vulvectomy and biopsy of the superficial inguinal lymph nodes. The pathologic specimen was interpreted to be a leiomyosarcoma ( Fig. 1) , with no metastatic tumors evident in the lymph nodes. Subsequently, she underwent adjuvant radiation, receiving 60 Gy to the pelvis.
After 2 years and 4 months, the patient presented with vulvar pain and was found to have a 1.5-cm recurrent mass in the left vulva. After a second resection, the histological diagnosis was a leiomyosarcoma. The patient underwent three chemotherapy cycles with irinotecan (CPT-11) and cisplatin (CDDP), comprising CDDP at 60 mg/m 2 body surface area (BSA) on day 1 plus CPT-11 at 60 mg/m 2 BSA on days 1, 8 and 15.
After another 2 years, she presented with vulvar pain and was found to have a palpable 3-cm recurrent mass in the left vulva, which was detected by pelvic MRI (Fig. 2) , and she underwent a third resection. Histology revealed that a bundle of fibrous tumor cells had invaded the connected tissue and muscular coat, and that there were some spindle-shaped and blunt-ended nuclei present. On immunohistochemical evaluation, the tumor cells exhibited strong and diffuse staining for c-kit and CD34, with no staining for desmin or α-smooth muscle actin (Fig. 3) . This recurrent tumor was diagnosed as a GIST and reevaluation of the original specimens also revealed a GIST (Fig. 4) . The patient was treated with imatinib at 400 mg/day. On day 13, she presented with systemic exanthema and immediately stopped taking imatinib. Later she restarted imatinib at a lower dose (100 mg/day) with administration of H1 antihistamine. No erythematous lesions developed, and the dose of imatinib was subsequently increased to 400 mg/day. The patient is currently healthy with no evidence of recurrence at 20 months after the last surgery.
Discussion
GISTs are the most common mesenchymal tumors of the gastrointestinal tract. They have gain-of-function mutations of the c-kit receptor tyrosine kinase gene and have been suggested to originate from ICCs (3). A small percentage of GISTs arise from extragastrointestinal masses in the omentum, mesenteries, retroperitoneum, rectovaginal septum and undefined abdominal sites. These tumors are occasionally designated as extragastrointestinal stromal tumors (5). Miettinen et al (6) reported that extragastrointestinal stromal tumors may not arise from ICCs, but instead may be multipotential neoplasms that exhibit divergent differentiation (Cajal cell-like or smooth muscle cell-like). The accurate rate of GIST occurrence is unclear. Miettinen et al (7) reported that GISTs most commonly occur in the stomach (60%), jejunum/ileum (30%), duodenum (4-5%), rectum (4%) and colon/appendix (1-2%). The prognosis of GISTs, including extragastrointestinal stromal tumors, is predicted by their size and mitotic rate. Consensus guidelines were issued to stratify GISTs by their size and mitotic rate into four categories according to the risks of aggressive behavior, i.e., very low, low, intermediate and high risk (8) . Complete excision should be performed whenever possible during treatment of a GIST. If the tumor is surgically incurable, adjuvant imatinib treatment has been approved (9) . Most adverse reactions to imatinib are mild to moderate and include nausea, diarrhea, myalgia, edema and cutaneous reactions. Approximately 31-44% of patients taking imatinib experience cutaneous reactions (10) . A rash is more likely to occur with higher doses and may therefore be a pharmacological effect rather than an immunogenic or hypersensitivity reaction. The rash generally responds to steroids, antihistamines and emollients. In addition, a gradual increase in the dose can reinstate imatinib therapy following resolution of the cutaneous eruptions (11) . In the present case, we were able to reinstate imatinib therapy at a lower dose with an antihistamine, and the patient is currently healthy with no evidence of recurrence at 20 months after the last surgery.
In conclusion, we have reported a rare case of a GIST that presented as a vaginal tumor. Gynecologists should be aware that GISTs may occur in this location, since a correct diagnosis is crucial for providing information and initiating imatinib therapy.
